South Korea: MFDS Approval Status for GLP-1 Drugs
South Korea's Ministry of Food and Drug Safety reviews GLP-1 drugs under its own national process, alongside a growing domestic biopharmaceutical sector.
By the GLP Semaglutide editorial team · Last updated December 30, 2025
South Korea's Ministry of Food and Drug Safety (MFDS) is the national regulator for drug approvals, including GLP-1 receptor agonists, operating a review process independent of the FDA, EMA, and other regional regulators.
A significant domestic biotech sector
South Korea has an active domestic biopharmaceutical industry with its own GLP-1 and related metabolic drug development programs, in addition to distributing approved products from multinational manufacturers.
Where to verify
MFDS publishes approval information through its official channels, which is the authoritative source for current status of any specific GLP-1 product in the South Korean market.
Primary sources